Investors cheer Akeso’s revenue milestone, even as it returns to the red
The drugmaker’s shares rallied after the release of its strong annual report, up by a cumulative 18% over the next three trading days Key Takeaways: Akeso’s drug sales rose 25%…
BRIEF: Hutchmed profit falls on shrinking R&D income
Hutchmed (China) Ltd. (HCM.US; 0013.HK; HCM.L), a biopharmaceutical company controlled by CK Hutchison Holdings (0001.HK), said its revenue fell 24.8% last year to $630 million, according to its annual results…
BRIEF: Ascentage Pharma prices U.S. IPO at 20% discount, to raise up to $130 million
Biopharmaceutical company Ascentage Pharma Group International (6855.HK) announced Friday that it will offer 7.325 million American Depositary Shares (ADS) in its upcoming U.S. listing at an issue price of $17.25…
BRIEF: Ascentage Pharma gets Chinese regulatory nod for U.S. listing
Biopharmaceutical company Ascentage Pharma Group International (6855.HK) received a listing approval notice from the China Securities Regulatory Commission (CSRC) on Monday, a necessary step before it can make an overseas…
PODCAST: A Biotech Buyout, and an Influencer Uprising
By Doug Young & Rene Vanguestaine AstraZeneca has offered to buy money-losing Gracell Biotech for up to $1.2 billion, in a first-of-its kind M&A for a Chinese drug startup. Will…
FAST NEWS: CMS Holdings Profit Rises as It Explores Medical Aesthetics
The latest: Drug maker China Medical System Holdings Ltd. (CMS Holdings) (0867.HK) on Wednesday evening said its net profit rose 19.2% last year to 3.02 billion yuan ($474 million), and…
FAST NEWS: 3SBio Sees Profit Doubling on Surging Revenues
The latest: 3SBio Inc. (1530.HK) released a positive profit forecast on Monday evening, estimating its net profit rose 100% to 120% for 2021, while its profit attributable to equity shareholders…
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
